Telaprevir
Mechanism :
Binds reversibly to nonstructural protein 3 (NS 3) serine protease and inhibits replication of the hepatitis C virus. Considered a direct-acting antiviral treatment for HCV, also called a specifically targeted antiviral therapy for HCV (STAT-C).
Indication :
- Chronic hepatitis C genotype 1 infection in combination with peginterferon alfa and ribavirin.
Dosing :
Pediatric safety and efficacy not established.
Adults:
The recommended dose is 1125 mg (three 375 mg tablets) taken orally twice daily (10-14 hours apart) with food for 12 weeks.
Adverse Effect :
Rash, fatigue, pruritus, nausea, anemia, diarrhea, vomiting, hemorrhoids, anorectal discomfort, dysgeusia
Interaction :
Digoxin: Telaprevir will increase the level or effect of digoxin by P-glycoprotein (MDR1) efflux transporter.
Ivosidenib: Ivosidenib and telaprevir both increase QTc interval.
Hepatic Dose :
Mild hepatic impairment: No dose adjustment recommended.
Moderate to severe hepatic impairment: Administration of the drug is not recommended.